Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01237288

Enrollment

Registered

2010-11-09

Start date

2010-09-30

Completion date

2013-07-31

Last updated

2013-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Hypophosphatemic Rickets

Brief summary

The purpose of this study is to investigate the efficacy and safety of oral phosphate (Z-521) in subjects with primary hypophosphatemic rickets.

Interventions

DRUGZ-521

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

1 Years to 14 Years

Healthy volunteers

Inclusion criteria

* Diagnosed as primary hypophosphatemic rickets based on familial history, genetic test or laboratory test results.

Exclusion criteria

* A hyperparathyroidism

Design outcomes

Primary

Measure	Time frame
Serum ALP level	6 month
Serum phosphate level	6 month

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 21, 2026